These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9313702)

  • 1. Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis.
    McKay CJ; Curran F; Sharples C; Baxter JN; Imrie CW
    Br J Surg; 1997 Sep; 84(9):1239-43. PubMed ID: 9313702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis.
    Johnson CD; Kingsnorth AN; Imrie CW; McMahon MJ; Neoptolemos JP; McKay C; Toh SK; Skaife P; Leeder PC; Wilson P; Larvin M; Curtis LD
    Gut; 2001 Jan; 48(1):62-9. PubMed ID: 11115824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis.
    Kingsnorth AN; Galloway SW; Formela LJ
    Br J Surg; 1995 Oct; 82(10):1414-20. PubMed ID: 7489182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet-activating factor.
    Kingsnorth AN
    Scand J Gastroenterol Suppl; 1996; 219():28-31. PubMed ID: 8865468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis.
    Wyncoll DL; Beale RJ
    Br J Surg; 1998 Feb; 85(2):279-80. PubMed ID: 9501837
    [No Abstract]   [Full Text] [Related]  

  • 6. The use of lexipafant in the treatment of acute pancreatitis.
    McKay C; Curran FJ; Sharples CE; Young CA; Baxter JN; Imrie CW
    Adv Exp Med Biol; 1996; 416():365-70. PubMed ID: 9131175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lexipafant fails to improve survival in severe necrotizing pancreatitis in rats.
    Rivera JA; Werner J; Warshaw AL; Lewandrowski KB; Rattner DW; Fernández del Castillo C
    Int J Pancreatol; 1998 Apr; 23(2):101-6. PubMed ID: 9629507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lexipafant and acute pancreatitis: a critical appraisal of the clinical trials.
    Abu-Zidan FM; Windsor JA
    Eur J Surg; 2002; 168(4):215-9. PubMed ID: 12440758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lexipafant in severe acute pancreatitis: the final word?
    Ulrich CD
    Curr Gastroenterol Rep; 2001 Apr; 3(2):85-7. PubMed ID: 11276374
    [No Abstract]   [Full Text] [Related]  

  • 10. The scientific basis of medical therapy of acute pancreatitis. Could it work, and is there a role for lexipafant?
    Imrie CW; McKay CJ
    Gastroenterol Clin North Am; 1999 Sep; 28(3):591-9, ix. PubMed ID: 10503138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis.
    Suputtamongkol Y; Intaranongpai S; Smith MD; Angus B; Chaowagul W; Permpikul C; Simpson JA; Leelarasamee A; Curtis L; White NJ
    Antimicrob Agents Chemother; 2000 Mar; 44(3):693-6. PubMed ID: 10681340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet activating factor antagonism reduces the systemic inflammatory response in a murine model of acute pancreatitis.
    Lane JS; Todd KE; Gloor B; Chandler CF; Kau AW; Ashley SW; Reber HA; McFadden DW
    J Surg Res; 2001 Aug; 99(2):365-70. PubMed ID: 11469912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with lexipafant ameliorates the severity of pancreatic microvascular endothelial barrier dysfunction in rats with acute hemorrhagic pancreatitis.
    Wang X; Sun Z; Börjesson A; Haraldsen P; Aldman M; Deng X; Leveau P; Andersson R
    Int J Pancreatol; 1999 Feb; 25(1):45-52. PubMed ID: 10211421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium.
    Schifitto G; Sacktor N; Marder K; McDermott MP; McArthur JC; Kieburtz K; Small S; Epstein LG
    Neurology; 1999 Jul; 53(2):391-6. PubMed ID: 10430432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severity of pancreatitis-associated gut barrier dysfunction is reduced following treatment with the PAF inhibitor lexipafant.
    Leveau P; Wang X; Sun Z; Börjesson A; Andersson E; Andersson R
    Biochem Pharmacol; 2005 May; 69(9):1325-31. PubMed ID: 15826603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a platelet-activating factor antagonist on pancreatitis-associated gut barrier dysfunction in rats.
    Andersson R; Wang X; Sun Z; Deng X; Soltesz V; Ihse I
    Pancreas; 1998 Aug; 17(2):107-19. PubMed ID: 9700940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New aspects of pharmaco-therapy for acute pancreatitis].
    Takase K; Ueda T; Kuroda Y
    Nihon Rinsho; 2004 Nov; 62(11):2074-8. PubMed ID: 15552891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early nonenhanced abdominal computed tomography can predict mortality in severe acute pancreatitis.
    Spitzer AL; Thoeni RF; Barcia AM; Schell MT; Harris HW
    J Gastrointest Surg; 2005; 9(7):928-33. PubMed ID: 16137586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hope or hype for lexipafant?
    Abu-Zidan FM
    Nature; 1998 Oct; 395(6701):431. PubMed ID: 9774090
    [No Abstract]   [Full Text] [Related]  

  • 20. Platelet-activating factor antagonism and streptokinase-induced hypotension in clinical acute myocardial infarction.
    Taylor R; Fatovich D; Hitchcock T; Morrison C; Curtis L
    Clin Sci (Lond); 2001 Jun; 100(6):601-7. PubMed ID: 11352774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.